7:04 am ISIS Pharm announces antisense targeting Of HBV produces dose-dependent reductions in hepatitis B virus in an animal model of HBV; data to be presented in April at the European Association for the Study of the Liver Meeting
View todays social media effects on ISIS
View the latest stocks trending across Twitter. Click to view dashboard
See who Isis is hiring next, click here to view
